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Abstract 
Background: Age-related insomnia is a condition affecting over so% of 
those aged 65 years and older, and is characterized by difficulties in sleep 
onset and maintenance. Poor sleep is associated with cognitive 
impairment, daytime sleepiness, injuries, and decreased quality oflife. 
Common insomnia pharmacologic therapies often result in side effects and 
the development of tolerance. 
Purpose: To review the evidence of the effectiveness of melatonin (MLT) 
for insomnia in adults 65 years and older? 
Methods: A priori study inclusion criteria included: study subjects aged 
65 or older, male or female; randomized, placebo-controlled trial; 
objective outcome measures to include either sleep log or diary, actigraphy 
and/ or overnight polysomnography. To identify relevant studies, articles 
published from 1966 to March 2004 were retrieved from the online 
databases: MEDLINE, CINAHL, Psychinfo, DARE, Cochrane, and EBM 
Reviews. MEDLINE (via PubMed) was searched using Medical Subject 
Headings (MeSH terms) "Sleep Initiation and Maintenance Disorders" 
and "Melatonin." A total of 121 English language journal articles were 
identified using this search strategy. All but 4 of these were excluded due 
to lack of randomization, inclusions of subjects less than 65 years, or 
failure to include objective data regarding sleep parameters. 
Results: Four crossover-designed studies of melatonin included 74 
insomniacs aged 65 years or older. In three of four randomized, placebo-
controlled trials, sleep efficiency was significantly improved compared to 
placebo, while sleep latency was significantly improved in two, with a 
trend toward significance in a third. In two others, total sleep time 
improved significantly. Further, in all but one of the included studies, 
melatonin significantly improved at least one actigraphic measure of sleep 
quality. 
Discussion: The results of this systematic review suggest that melatonin 
may be effective in improving two objective measures of insomnia, sleep 
efficiency and sleep latency. Although melatonin may be a safe alternative 
to standard hypnotic therapy, its use will be limited until more 
information is available regarding appropriate patient selection and 
dosing, especially when effective therapies exist (e.g., cognitive behavioral, 
standard hypnotics). This information will need to be obtained from much 
larger, well-designed, randomized controlled trials. 
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Burden of Suffering from Insomnia 
Definition of Insomnia 
Insomnia is a disorder characterized by a difficulty initiating or 
maintaining sleep and results in daytime dysfunction.' The definition of 
insomnia can be either primary or secondary depending on cause. To 
distinguish, the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) advises using the term primary insomnia when there is not an 
additional medical or psychiatric disorder that could be precipitating the 
sleep disturbance. The International Classification of Sleep Disorders 
(ICSD), however, does not use the term primary insomnia but 
differentiates three subtypes of insomnia (psychophysiological, sleep state 
misperception, and idiopathic).' 
For the purposes of this review, the term primary insomnia from 
the DSM-IV (which encompasses the three subcategories of the ICSD) will 
be used. Since insomnia directly related to neurodegenerative disorders, 
depression, medical comorbidities may be different from primary 
insomnia; they will be excluded from this review. Further, since there is 
no specific definition for "age-related insomnia," the complaints most 
research authors have used as the definition of insomnia will be used in 
this review. These complaints include one or more sleep disturbances that 
are associated with daytime consequences, occur three or more time per 
week and last a minimum of six months. 
3 
L 
Etiology and Pathophysiology 
The basic classification of insomnia is based on the duration of 
complaints, whether acute or chronic.2 The exact duration of sleep 
complaints that justifies one diagnosis over another varies among authors 
and sources. Transient insomnia is referred to when sleep problems and 
complaints last less than two to four weeks. Chronic insomnia generally is 
regarded as complaints that persist longer than one month.'·3 
Acute or transient insomnia often is closely related to a variety of 
L precipitants. Examples of precipitants seen in older adults include 
environmental alterations, grief or bereavement, and/or medical illness.' 
Interestingly, sleep of older adults without medical or psychiatric illness 
may be more similar to those of younger persons. 4 
Chronic insomnia patients may have many factors contributing to 
their condition and a specific precipitant may be less obvious or absent.' 
The exact physiologic mechanism of primary or chronic insomnia, 
unrelated to those associated with transient insomnia noted above, is 
unclear. Some have suggested that chronic insomniacs may be over-
stimulated and hyper-aroused. Many of these patients have been noted to 
exhibit increased metabolic rates and body temperatures compared with 
healthy controls.' 
Among the elderly, age-related changes in the circadian rhythm also 
may lead to poor sleep.s The circadian pacemaker (or clock), located in 
the suprachiasmatic nucleus (SCN) of the hypothalamus, regulates many 
physiologic functions and the sleep/wake cycle. Abnormalities of this 
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system may lead to poor sleep.6.7,s The concept that sleep may be 
disturbed by alterations in the circadian system of older persons is 
supported by decreased circadian rhythm amplitude and an advance 
phase-shifted rhythm, manifested clinically by earlier sleep onset and 
wake times.9 Disturbances of sleep quality and duration also may be 
related to the fact that older adults generally have more abnormalities of 
sleep initiation (i.e., the time it takes to fall asleep), sleep maintenance 
(i.e., the ability to stay asleep), sleep efficiency (i.e., the time asleep/time 
in bed), sleep duration and nocturnal awakenings or arousals.'0 Although 
any of these sleep parameters may be altered in the elderly, larger 
disturbances have been reported in sleep duration and the ability to 
maintain sleep, as opposed to sleep initiation." Consequently, older 
persons often have more fragmented sleep and daytime napping than 
younger controls. s 
Prevalence of Insomnia 
Age-related insomnia is a common complaint ofthe elderly. In a 
large sample of greater than 6,ooo subjects, the National Institute on 
asleep (sleep initiation), and 42 percent reported problems with both l Aging found that 28 percent of older adults reported problems falling 
falling asleep and staying asleep (sleep maintenance)? In a telephone 
survey conducted by the National Sleep Foundation (NSF) in 2003, 1506 
community-dwelling subjects between the ages of 55 and 84 were 
interviewed about their sleep. Overall, nearly one-half (48 percent) of 
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older adults reported having one or more symptoms of insomnia at least a 
few nights per week.12 Further, although the prevalence of insomnia 
among primary care patients has been estimated to be greater than 50 
percent, less than one-third of these patients report their complaints, and 
much less receive treatment.'3-'4-'5 
Morbidity from Insomnia 
Insomnia among older adults causes significant morbidity. In the 
above recent NSF survey, 38 percent of persons who reported excellent or ~-
very good quality of overall health were less likely to have symptoms of 
insomnia more than a few nights a week. That compares with 71 percent 
of those reporting fair or poor quality of health. Similarly, 42 percent of 
those reporting excellent or very good memory were less likely to have 
symptoms of insomnia compared to 68 percent for those with fair or poor 
memory.12 Sleep abnormalities often cause significant daytime sleepiness 
that results in slower reaction times, impaired mental abilities, increased 
rates of injuries, gait and balance instability and a decreased self-reported 
health status.'6 
There is some evidence that insomniacs also have greater rates of 
healthcare utilization due to an increased rate of accidents. After 
adjustments for age, gender, BMI and study site, 6,440 participants from 
the Sleep Heart Health Study (SHHS), reported that those with self-
reported insomnia were noted to have an increased Chronic Disease Score 
(CDS). Although the increases in CDS were modest, due to the high 
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prevalence rates of insomnia in the general population, these increases 
may be associated with a cost burden for the U.S. healthcare system. A 
potential limitation of this study may include a selection bias. This cohort 
consisted of subjects already involved in epidemiologic research and thus 
may have more healthcare contact than the general population. Another 
problem may have been a measurement bias, since the authors did not 
measure direct health costs, but a surrogate marker, CDS score. 17 
Furthermore, patients suffering from insomnia may be at a higher 
risk of developing an affective disorder, such as depression or anxiety. 
Traditionally, insomnia has been considered secondary to depression. This 
may not necessarily be the case in all circumstances. 1s In a large 
European population-based telephone study of 14,915 subjects, aged 15 to 
100 years, 40 percent of those with affective disorders reported insomnia 
appearing before any mood disorder symptoms. In 38 percent of the cases, 
insomnia appeared at the same time as the anxiety disorder and in 34 
percent, after the anxiety disorder.'9 Other longitudinal studies have 
reported that insomnia is a risk factor for the development of depression,20 
but whether depression causes insomnia - or vice versa- is unclear.'s 
Dependency of older insomnia patients on alcohol and hypnotic 
medications also is a concern since this dependency may precipitate sleep 
abnormalities, lead to tolerance and addiction, cause cognitive difficulties, 
and worsen other comorbidities.22 Alcohol often is used as a sleep aide for 
patients suffering from insomnia. While it is true that alcohol 
consumption may initially lessen sleep latency, as it is metabolized, it 
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typically causes more sleep fragmentation and nighttime arousals. Due to 
a prolonged metabolism in the elderly, alcohol becomes a much more 
potent hypnotic but with increased side effects.'6 
The use of over-the-counter sedating agents (e.g., antihistamines) 
and prescription sedative hypnotics (e.g., benzodiazepines) also is 
problematic in the elderly. These agents may have significant side effects; 
probably most important of these is gait abnormalities and subsequent 
falls. The etiology of falls in older adults is usually multifactorial and not 
related to one cause.23 In a recent large study, benzodiazepines were 
t-
shown to be associated with a significantly increased risk of falls in women 
aged 65 years of age and older.24 However, the true association of hip 
fracture and benzodiazepine has been less clear.25,26,27 
In a case-controlled study by Pierfitte and coworkers, 245 persons 
older than 65 years presenting to a university emergency department with 
hip fracture were compared against 817 controls. Benzodiazepines use was 
determined from medical records, questionnaires, or plasma samples at 
admission. Benzodiazepine use, except for lorazepam, was not associated 
with increased odds of hip fracture (OR 0.9, 95% CI 0.5, 1.5). Since 
controls were selected from other hospital admissions, their drug use 
(including benzodiazepines) may be higher than a healthy control 
population, and the association between benzodiazepine usage and hip 
fracture may have been lessened.28 In the prospective cohort study of 
8,127 older women, Ensrud and associates found no statistically 
significant increase in risk of hip fracture among women taking 
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benzodiazepines after adjustment for multiple risk factors (Adj. RR 1.20, 
95% CI 0.72, 2.00). Additionally, no association was found between those 
taking long- or short-acting preparations and hip fractures.27 In contrast 
to these reports, a 2003 review ofbenzodiazepine use and hip fracture, 
Cumming and Couteur identified 11 primary epidemiologic studies. After 
excluding four hospital-based, case-controlled studies (due to difficulties 
finding appropriate controls), and one other comprised only of 
institutionalized subjects, the authors reported an increased risk of hip 
fracture ofless than so percent among the remaining six high-quality 
studies.29 
Benzodiazepines also may be associated with increased rates of 
motor vehicle crashes. In a case-controlled study of 19,386 UK drivers 
between Aug 1, 1992, and June 30, 1995, 235 drivers taking a 
benzodiazepine were involved in a traffic accident and had an increased 
odds of accidents compared to controls (OR 1.62, 95% CI 1.24,2.12).3° In 
another case-controlled designed study of 224,734 elderly Canadian 
drivers, 5,579 injurious automobile crash were reported. The use oflong-
acting benzodiazepine medications but not short-acting ones, were 
associated with an increased odds of automobile accidents (1-45, 95% CI 
1.04,2.03).31 
Treatments for Insomnia 
There are several therapeutic strategies available for older adults 
suffering from insomnia. Most common strategies include cognitive-
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behavioral techniques, environmental modifications and as mentioned 
above, pharmacotherapy. 
Non-pharmacologic 
Cognitive behavioral therapies usually include efforts to improve 
sleep hygiene, and often include: 1) limiting daytime napping, 2) limiting 
stimulant consumption (e.g., caffeine and nicotine), 3) using the bed for 
sleeping and sex only and 4) keeping a regular sleep schedule or routine.2 
Other effective methods might include sleep restriction and stimulus 
control.32,33,34,3s Environmental modifications for age-related insomnia 
often include stimulus control and bright-light therapy for those suffering 
from phase-shift disorders, in an attempt to delay, or phase-shift their 
circadian rhythms and consolidate sleep time. 36, 37, 38, 39, 4o 
In a recent meta-analysis comparing the efficacy of pharmacologic 
and cognitive behavioral therapies (stimulus control and/or sleep 
restriction) revealed comparable treatment effects in most outcome 
variables studied (total sleep time, nighttime awakenings and sleep 
latency) except in regards to sleep latency, which was significantly reduced 
in the behavioral trials compared to those using pharmaceuticals. Due to 
wide confidence intervals between mean treatment differences and the L 
f 
timing of benzodiazepine administration in many trials (often just before ' 
bedtime) which more than likely effected sleep maintenance, the true 
difference of sleep latency may be somewhat more modest.'3 
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A major limitation of cognitive behavioral therapies for those 
patients with transient insomnia is cost. Hypnotic agents used for 30 days 
are much less expensive than multiple behavioral education sessions.'3 In 
terms of chronic insomnia, these cost differences may be minimal, 
especially when other studies suggest that behavioral therapies may 
provide more long-lasting improvement in sleep outcomes. In a 1999 
review of non pharmacologic treatment for chronic insomnia, Morin and 
colleagues reported that a majority of patients achieved good outcomes 
with a variety of behavioral therapies. Despite these findings, the authors 
found limited evidence that improved sleep in these studies resulted in 
improved daytime function.4' 
Pharmacologic 
Pharmacotherapy for insomnia usually involves benzodiazepine 
hypnotics. Due to the serious side effects associated with hypnotics in this 
population, as mentioned above, newer short-acting, non-benzodiazepine 
agents (e.g., zolpidem and zaleplon) have been increasingly prescribed. 
Although these agents generally are considered safer than other hypnotics, 
current recommendations suggest that they be used infrequently and for 
short periods for transient insomnias. Chronic use of any hypnotic is 
generally discouraged, due to side effects and difficulties with 
withdrawal.22 Further, these agents slow metabolism and thus increase 
drug concentrations as well as interactions with other medications taken 
by elderly patients.42 
II 
Nonprescription, or "over-the-counter," sleep aides are frequently 
used by older insomniacs. Sedating antihistamines, alcohol, and 
melatonin are some of the more common agents. Sedating antihistamines 
often are successful at promoting sleep onset or decreasing sleep latency, 
but the development of tolerance, anticholinergic side effects and morning 
drowsiness, limit their usefulness. Alcohol is another popular substance 
used by older patients for the promotion of sleep initiation. 
Notwithstanding the other significant adverse consequences of alcohol in 
this population, 43 the limitation of alcohol as a sedative hypnotic includes 
increased sleep disruption, particularly during the later sleep period when 
alcohol levels decrease due to metabolism, and the development of 
dependence. 22 
Melatonin 
Melatonin is a derivative of tryptophan, which is produced and 
secreted from the pineal gland. The secretion of melatonin is regulated by 
light and dark periods. During daylight hours, light impulses sent from 
the retina to the suprachiasmatic nucleus of the hypothalamus, inhibit 
beta-adrenergic sympathetic outflow and thereby decrease melatonin 
secretion. Dark periods have the opposite effect, stimulating sympathetic 
flow to the pineal gland and promoting melatonin secretion. 
Correspondingly, serum levels of melatonin have been shown to peak 
during evening hours but remain low during daytime. Melatonin 
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suppression occurs only with ocular light but not with extraocular light, 
such as light directed toward the popliteal fossa, or constant dim light. 44, 45 
Melatonin, as opposed to sedative hypnotics, has a low side effect 
profile. In a study to determine adverse effects associated with 28 days of 
therapy with 10mg of melatonin, multiple laboratory outcome measures 
were assessed. Results indicated no toxicologic effects of melatonin over 
this one-month period. 46 In another study, however, endogenous 
melatonin secretion, reflected by a drop in core body temperature, was 
associated with decreased cognitive processing.47 There also is some 
preliminary evidence that melatonin may have a negative impact on 
orthostatic tolerance in the general population. 48 In attempt to evaluate 
the potential effects of melatonin premedication for preoperative 
anxiolysis, melatonin was found to be associated with anxiolysis and 
sedation without cognitive or pyschomotor side effects. It was not, 
importantly, found to decrease recovery.49 One potential limitation of 
melatonin is a concern over orthostatic hypotension. 
Discovered in 1958 by Lerner et al, the hypnotic effects of melatonin 
have been shown in healthy persons. Melatonin administered to a group 
of healthy young men was associated with a significant correlation 
between salivary melatonin levels and the timing of increased subjective 
sleepiness.so 
Melatonin has been used to promote sleep in a variety of 
conditions, circumstances and populations. In conditions such as jet lag 
and some circadian rhythm sleep problems, melatonin has been shown to 
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be somewhat effective. 51 In patients with schizophrenia, melatonin was 
found to improve sleep efficiency in those whose sleep quality was poor.s2 
In medically ill patients with transient insomnia, melatonin was found to 
significantly decrease sleep latency, increase sleep duration and improve 
sleep depth without causing daytime dysfunction.s3 Melatonin also has 
been recently shown to improve circadian rhythms in some blind 
patients.s4 The effectiveness of melatonin in older adults with insomnia 
has been less studied. 
The available literature regarding endogenous melatonin's ability to t--
initiate and promote sleep maintenancess and reports suggesting that 
decreased serum levels of melatonin are associated with sleep disorders,s6 
has prompted studies to evaluate melatonin supplementation. This, 
coupled with evidence suggesting that there are age-related declines in 
melatonin circulating levels,s7. ss, 59, 6o and even lower levels in primary 
insomniac patients compared with normal sleepers (45 v. 6o pg/ml, 
respectively),61 have led researchers to hypothesize that exogenous 
melatonin may be useful in the treatment of insomnia in older adults.ss In 
addition, not only do older adults produce less melatonin, they may also 
have more difficulty responding to the hormone that is secreted. This 
supports the theory that there may be a lessened response to the L 
hypothermic effects of melatonin in elders. 6z, 63 The purpose of this review 
is to examine the available evidence for melatonin supplementation in 
older insomniacs and - based on these findings - whether melatonin 
should be recommended as a therapy for this population. 
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Methods 
To identify relevant articles, articles published from 1966 to March 
2004 were retrieved from the online databases: MEDLINE, CINAHL, 
Psychlnfo, DARE, Cochrane and EBM databases. MEDLINE (via PubMed) 
was searched using Medical Subject Headings (MeSH terms) "Sleep 
Initiation and Maintenance Disorders" and "Melatonin." A research 
librarian was consulted to assist in this systematic search. 
Articles and abstracts were reviewed by the author for 
appropriateness and all potentially relevant articles identified by the 
search were evaluated for inclusion in the analysis. To be included, studies 
must have 1) a randomized placebo-controlled design, 2) included only 
subjects 65 years of age and older (male or female), 3) provided 
information concerning participant-oriented outcomes (sleep efficiency, 
duration, maintenance, and/or awakenings) and described the objective 
instruments used (i.e., sleep log, sleep diary, actigraphic and/ or overnight 
polysomnographic) and 4) included results for both treatment and control 
groups. 
A summary of included articles, describing design, subjects, 
intervention evaluated, outcomes measures, and methological quality, is 
presented in Table 1. Any article that failed to meet any of the stated 
inclusion criteria was excluded from further analysis. Exclusion criteria 
included study designs other than randomized placebo-controlled (i.e., 
case-controlled, case reports, case series, animal studies, and 
observational studies), non-English language articles, subjects with other 
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primary sleep disorders (i.e., obstructive or central sleep apnea, restless 
legs syndrome, or periodic leg movements of sleep), other comorbidities 
that affect sleep, specifically dementia and/ or depression. 
Each article was assigned a grade of "pass" or "fail" for each of the 
stated inclusion/ exclusion criteria. The author graded articles and 
assessed methodologic quality of each included trial using modified 
criteria of Khan and associates.64 The criteria components included: 1) 
specified eligibility criteria, 2) concealment of allocation, 3) similarity of 
groups at baseline, 4) randomization of treatment groups, 5) blinding to 
allocation, patient, and provider, 6) point estimates for the primary 
outcome measures, and 7) intent-to-treat analysis. Studies were rated as 
"good," "fair," or "poor." A "good" rating suggested that the study 
adequately addressed all quality criteria; a "fair" rating suggested the trial 
did not adequately all quality indicators; and a "poor" rating was assessed 
if the trial contained a fatal flaw that invalidated the study results. 
Results 
A total of 121 English language journal articles were identified using 
this search strategy, of which four randomized, placebo- controlled trials 
were identified and met the inclusion criteria for this review. All of the 
trials were of a crossover design (Haimov et al., 1995; Garfinkel et al., 
1995; Garfinkel et al., 1997; Baskett et al., 2003). 65, 66, 67,68 Six reports did 
not meet inclusion criteria due to design, and included: abstract, research 
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letter, retrospective case study and three open-label studies. Twelve 
randomized, placebo-controlled trials of melatonin were excluded because 
subjects did not have insomnia or were younger than age 65 years of age. 
Six other randomized, placebo-controlled trials were further excluded, 
even though they included subjects older than 65 years, because no 
subgroup analyses by age was performed. The majority of other reports 
were excluded due to inclusion of subjects with cognitive impairment, 
bipolar disorder or depression. 
Outcome Measures 
Each included study reported actigraphic measures of sleep 
quality effects of melatonin in older insomniacs. The measurements that 
were calculated and reported in each of the four studies include: sleep 
latency (time in minutes to fall asleep) and sleep efficiency (calculated by 
dividing time asleep over total sleep period, and reported as a percent). 
The following actigraphic outcome measures were not consistently 
reported, and include: activity level during sleep period (the mean sum of 
actigraphic movements recorded during sleep divided by sleep duration) 
(Haimov et al., 1995), number of awakenings (Garfinkel et al., 1997; 
Baskett et al., 2003), awake after sleep onset (Garfinkel et al., 1995; 
Garfinkel et al., 1997) and total sleep time (Garfinkel et al., 1995; Garfinkel 
et al., 1997; Baskett et al., 2003). Empirical data of self-reported sleep 
quality, based on the Pittsburgh Sleep Quality Index (PSQI) score, was 
reported only in the study by Baskett, et al., 2003. All studies measured 
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continuous actigraphy outcome endpoints repeatedly over consecutive 
nights (ranging from 3 to 7) in order to decrease intra-patient variability 
and thus increase statistical power. A summary of results is presented in 
Table 2. 
An actigraph is a wrist-worn device that uses an accelerometer to 
record wrist movements and automatically differentiates between sleep 
and wake states. It has been used in clinical trials to discriminate between 
sleep and wake episodes and correlates highly with polysomnographic 
measures. 69 More importantly, actigraphy has been shown to be 
sufficiently sensitive to detect the effects of insomnia treatments in elderly 
subjects.7° It has the additional benefit of the ability to assess sleep for 
longer durations in more natural circumstances and environments (i.e., 
subjects are at home and in their own beds).71 
Summary of Studies 
Haimov et al., 1995 
Hiamov and colleagues recruited (n=26) patients with reported 
sleep problems on at least three evenings per week if those problems were 
present for at least six months. (An elderly group without insomnia was 
included in the baseline but was not included in any of the treatment 
arms). The subjects with insomnia were either community-dwelling 
(n=S), or institutionalized (n=18). None of the subjects suffered from 
dementia on Mini-Mental Status Exam (MMSE), or depression on the 
Hamilton rating scale, however, no specific criteria were reported in the 
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text regarding cut-offs. The potential subjects were then interviewed by an 
experienced physician to rule out other medical reasons for sleep problems 
or other primary sleep disorders. Since a priori hypothesis of this study 
was that elderly insomniacs classified as melatonin-deficient, peak 
secretions of melatonin were evaluated and found to be lower in the both 
insomnia groups. 
After a placebo run-in period of one week, both groups of insomnia 
subjects received 2mg of fast-release, slow-release or placebo during three 
experimental periods (including a two-week wash-out period between 
each period). To determine if tolerance or side effects developed, a two-
month period of either 1mg melatonin or placebo was used. Actigraphic 
measurements recorded activity during all treatment periods, except for 
the last two-month period when recording was monitored only during the 
last week of therapy. To limit intra-subject night-to-night variability, 
actigraphic measures for each subject were averaged over the week. 
Outcome analysis included all 26 subjects for sleep efficiency and activity 
but due to institutional bedtimes, institutionalized subjects were not 
included in sleep latency analysis. 
In this study, the 2mg slow-release formulation of melatonin 
revealed a significant improvement in sleep efficiency (80-4 v. 77-4%, 
L 
p=o.oo8) and sleep latency (37 v. 54, p=0.05). Sleep latency also 
significantly improved with a 2mg fast-release melatonin formulation as 
compared to placebo (32 v. 54 minutes, p=0.05). There was also statistical 
improvements in sleep latency (14 v. 54, p=0.05), sleep efficiency (84.3 v. 
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77-4, p<0.001) and activity levels (18.6 v. 26.9, p<0.001) in the open-label, 
two-month trial1mg sustained-released melatonin, but conclusions from 
this treatment arm may be more problematic due to lack of blinding of 
treatment groups. 
How and where the subjects were recruited was not clearly 
identified in the article. Although eligibility criteria were clearly specified, 
there may be selection bias since both institutionalized and community-
dwelling subjects were included in the insomnia group and it is unclear if 
subjects were truly similar at baseline. Subject randomization was 
reported but details of assignment and method of concealment were not 
described. Although the study was reportedly conducted in a double-blind 
manner, the allocation process was not described in the paper. Only three 
subjects withdrew from the study but reasons for withdrawal were not 
described and there was no mention of intent-to-treat analysis reported. 
There was no sample size calculations reported in the article. The 
continuous variables of actigraphic outcome measures were analyzed 
using paired t-tests, reporting means, standard deviations, and 
significance levels of <o.os. 
Garfinkel et al., 1995 
Elderly insomniacs (n=12) were included in the randomized, 
double-blind, crossover study by Garfinkel and colleagues (1995) of 
controlled-release melatonin on sleep quality indicators among elderly 
insomniacs. The subjects were recruited after a sleep disorders lecture at 
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senior center. All were independently living and three out of the initial15 
were excluded because of dementia or limited compliance. All subjects 
were taking at least one type of sleep medication (types not reported). 
Melatonin (2mg slow-release) or placebo was administered to subjects 
over three weeks, and then, after a one-week washout period, were given 
the other preparation. 
After each three-week treatment period, nighttime sleep was 
assessed with actigraphy over three consecutive nights. Each of the sleep 
variables was averaged for each subject. Urinary 6-suphatoxymelatonin 
(6-SMT), the metabolite from melatonin, and a surrogate for serum levels, 
were measured from each participant prior to treatment periods to 
estimate peak overnight secretion. 
Garfinkel et al., 1995, however, did report a statistically significant 
change in sleep efficiency between melatonin group and placebo groups 
(83% v. 75%, p <0.001) and in wake after sleep onset (in minutes) (73 v. 
49, p<O.OOl). There was a trend towards significance among groups in 
terms of sleep latency (p <o.o88), but not in total sleep time. 
Eligibility criteria were used to limit confounding by excluding 
known conditions that affect sleep and were clearly specified in the article. 
Due to the crossover study design, the control and intervention groups 
were similar at baseline. Subjects were randomized and the pharmacist 
preparing the containers knew randomization codes. Treatment codes 
were broken only after study results were obtained. During the treatment 
periods, investigators and subjects were blinded to intervention. All 
21 
randomized subjects completed the study and no data was reported 
missing. No references to power calculations were reported. The 
continuous variables of actigraphic outcome measures were collected 
equally among groups and analyzed using two-tailed t-tests, reporting 
standard errors and significance levels of <0.05. 
Garfinkel et al., 1997 
In 1997, a new study by Garfinkel, Laudon, and Zisapel enrolled 
(n=21) elderly subjects who complained oflong-term insomnia and who 
also were currently using a benzodiazepine. Study design mirrored the 
protocol of the previous study by Garfinkel et al., 1995, described above. 
Recruitment was in a similar manner to the previous study by the author. 
Similar measurements of urinary 6-MT were collected and reported. 
Garfinkel et al., 1997, in contrast to their previous study, showed a 
significantly higher percent of sleep efficiency among those taking 
melatonin as compared to placebo, 83 percent v. 75 percent (p<o.oo1), 
respectively. Melatonin treatment also had a significant effect compared to 
placebo on decreasing sleep latency (19 v. 33 minutes, p=0.007) and also 
significantly shortened the amount of time spent awake after sleep onset 
(49 v. 73 minutes, p<0.001). Total sleep time or sleep duration also was 
significantly improved with melatonin treatment compare to placebo (360 
v. 365 minutes, p=0.027) and the number of awakenings was lower in the 
melatonin group, 11.4 v. 16.2, p=0.004) Further, reported side effects 
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included only two cases of pruritis, one in the treatment and one in the 
control group. 
Eligibility criteria were clearly specified in the article and due to the 
crossover study design the control and intervention groups were similar at 
baseline. Randomization and blinding were similar to the study by 
Garfinkel, et al., 1995, reported above. All 21 randomized subjects 
completed the study and no data was reported missing. A priori sample 
size estimates were not reported in the article. The continuous variables of 
actigraphic outcome measures were analyzed using two-tailed t-tests, 
reporting standard deviations and significance levels of <o.os. 
Baskett et al., 2003 
More recently, Baskett and colleagues (2003) studied the effects of 
melatonin in elderly insomniacs (n=20 ). Subjects were recruited from 
advertising and screened with a questionnaire (Pittsburgh Sleep Quality 
Index) by mail. Exclusion criteria were determined during a clinical 
interview and were the most stringent of all the included studies. Subjects 
were excluded for advanced or delayed sleep phase syndrome, poor sleep 
hygiene, changes in medications during the study, use of hypnosedatives, 
low creatinine clearance and medical conditions significantly interfering 
with sleep. Subjects with a MMSE below 26 (out of 30) points or a score of 
six or more on the Geriatric Depression Scale (GDS) were also excluded 
from enrollment. The 20 subjects were randomly chosen from 60 
problem-sleeping persons who met inclusion criteria for enrollment. 
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During the trial, five of these subjects withdrew (two due to poor health, 
two due to adverse reaction and one changed their mind), leaving 15 for 
analysis. 
Subjects were given 5mg of fast-release melatonin or placebo to be 
taken prior to retiring to bed. Melatonin or placebo was each taken for 
four weeks, separated by a washout period. Actigraphic watches were 
worn on the subject's non-dominant wrist for five consecutive nights 
during the last week of each trial period. Baskett et al., 2003, reported no 
significant changes among any of the actigraphic measures of sleep quality 
between active treatment and placebo groups of poor sleepers. There also 
were no significant differences between self-reported sleep quality on the 
PSQI between treatment groups. 
In an attempt to limit selection bias and confounding, subjects with 
conditions or disorders that are known to negatively effect sleep (e.g., 
sleep disordered breathing, cognitive impairment) were excluded. Other 
eligibility criteria were clearly specified in the article and treatment groups 
were similar at baseline. Randomization and blinding were reported and 
appeared adequate. Of the 20 subjects randomized to receive placebo or 
melatonin, only 15 completed the trial. Sample size calculation were based 
on an earlier pilot study, and included: 1) 15-minute change in sleep 
latency, 2) six percent change in sleep efficiency and 3) a 0.6 decrease in 
the number of awakenings. This estimate required 12 participants in each 
group (a=0.05, ~=So%). Since no intent-to-treat analysis was reported 
regarding the five subjects who withdrew after randomization but before 
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the treatment period, the possibility of attrition bias must be considered. 
Due to small sample sizes and skewed data, the median of the continuous 
outcome measures, standard deviations and 95 percent confidence 
intervals were reported. The continuous variables of actigraphic outcome 
measures were analyzed using two-tailed t-tests, reporting standard 
deviations and significance levels of <0.05. 
Discussion 
In this systematic review of the effectiveness of melatonin use in 
patients over 65 years of age, only 74 total subjects were studied. In three 
of four randomized, placebo-controlled trials, sleep efficiency was 
significantly improved compared to placebo, while sleep latency was 
significantly improved in two, with a trend toward significance in a third 
(Garfinkel et al., 1995). In two others (Garfinkel et al., 1995+1997), total 
sleep time improved significantly. Further, in all but one of the included 
studies, melatonin significantly improved at least one actigraphic measure 
of sleep quality. 
Limitations 
Since only English-language articles were included in this review 
there may have been a publication bias. Another limiting factor of the 
included studies was the small sample sizes. Even though all of the 
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included studies were of a crossover design, the generalizability of the 
results may be lessened. 
In terms of subject variability among studies, a potential limitation 
of both studies by Garfinkel, et al., 1995 & 1997, may be the fact that 
subjects were to taper their dose ofbenzodiazepines during the study. 
Thus, the positive effects of melatonin may have been confounded by 
ongoing or previous hypnotic therapy. 
Two proposed mechanisms of potentiation were suggested in this 
study.67 Melatonin has been shown to increase benzodiazepine receptor 
binding in animal models and benzodiazepines themselves may decrease 
endogenous melatonin secretion. However, since insomnia patients often 
are prescribed these agents, their use in experimental subjects may be 
more representative of this population. Interestingly, in a later article by 
Garfinkel, et al., 1999, controlled-released melatonin appeared to facilitate 
benzodiazepine discontinuation without worsening any sleep quality 
indicator.71 
Selection bias may complicate the internal validity, especially the 
studies by Garfinkel, et al., 1995 & 1997. In both studies, subjects were 
recruited from a senior center after a lecture on sleep disorders and may 
represent a highly motivated population. Other sources of selection bias 
may be found in Haimov, et al., 1995. In this trial, not only did the authors 
fail to document recruitment procedures, they also included insomnia 
participants who were both community-dwelling and residents of nursing 
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homes. Due to comorbidities, decreased activity levels and medication 
usage, these two groups may be too dissimilar to group together. 
Baskett, et al., 2003, on the other hand, may have been too 
restrictive in subject inclusion. Their exclusion criteria may have self-
selected an unrepresentative healthy population that does not accurately 
represent the vast majority of elderly persons. 
Other potential threats to internal validity and clinical usefulness of 
these studies may include the lack of reported outcome measures of sleep 
quality. Even though all studies reported using a subjective sleep quality 
instrument in their enrollment, only Baskett, et al., 2003, reported results 
after treatment (which was not significantly different between groups). 
Since a daytime dysfunction is considered part of the diagnostic criteria for 
insomnia, this omission may be problematic. 
Are the results of this review consistent with prior studies? 
In a previous review by Rikkert and Rigaud (2001), six randomized, 
placebo-controlled trials were included. Three of the studies in that review 
were excluded in this present review since subjects in those studies 
included some less than age 65 years and one also had subjects with mild 
cognitive impairment or dementia. Results from this systematic review 
found that sleep latency decreased in four of the six included studies, and 
that other indicators of sleep quality (sleep efficiency, total sleep time, and 
wake time after sleep onset) improved in three. The authors' conclusions 
did, however, support the use of melatonin for elderly patients suffering 
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from insomnia, especially if they had lower than normal nighttime 
melatonin levels and/ or were taking benzodiazepines. 72 
A few studies of middle-aged and older insomniacs not meeting this 
review's inclusion criteria suggest evening melatonin may be effective in 
improving sleep quality and duration. n 74,75 In a study of the effects of a 
single evening dose of melatonin (0.3 mg and 1.0 mg orally) on 
polysomnographic measured sleep in 15 healthy middle-aged volunteers 
using a placebo-controlled, double-blind, crossover design, 1.0 mg dose of 
melatonin significantly increased actual sleep time, sleep efficiency, non-
REM sleep and REM sleep latency. 6I A significant increase in the 
subjective assessment of total sleep time and daytime alertness was 
demonstrated with melatonin but not with placebo.73 In an open pilot 
study on the efficacy of melatonin in the treatment of sleep disorders, 
patients with sleep disturbances alone, patients with sleep disturbances 
and signs of depression, and patients with sleep disorders and dementia 
received 3 mg melatonin p.o. for 21 days, at bedtime. After two to three 
days of treatment, melatonin significantly augmented sleep quality and 
decreased the number of awakening episodes in patients with sleep 
disturbances, whether those episodes were associated with depression or 
not. Estimates of next-day alertness improved significantly only in patients 
with primary insomnia.76 
There appears to be more evidence supporting the use of melatonin 
as an agent decreasing sleep latency. The effects of immediate-release 
melatonin on circadian rest-activity profiles, cognition and mood were 
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investigated in 10 elderly individuals with self-reported sleep-wake 
disturbances. Melatonin (6 mg) administered two hours before habitual 
bedtime enhanced the rest-activity rhythm and improved sleep quality as 
observed in a reduction in sleep onset latency and in the number of 
transitions from sleep to wakefulness. However, total sleep time was not 
significantly increased nor was wake within sleep significantly reduced. 
The ability to remember previously learned items improved along with a 
significant reduction in depressed moods. No side effects or 
contraindications were reported by any of the participants during the 10-
day trials. These results suggest that melatonin can safely improve some 
aspects of sleep, memory and mood in the elderly in short-term use.77 
In anotller study, the effects of 5mg melatonin administration on 
sleep latency among elderly patients (older than 55 years of age) were 
compared with a placebo group. Exogenous melatonin resulted in 
statistically significant reduction in sleep latency between good and poor 
sleepers.7s 
Other studies are more consistent with results from Baskett, et al., 
2003. In a recent study, Almeida, et al., reported no significant 
improvement in any sleep indicator of 10 primary insomnia patients, 
ranging in age from 30-72 years, who took melatonin (0.3mg and Lomg) 
or placebo.79 The limited or lack of improvement in sleep after evening 
melatonin dosing has been reproduced in other trials as well. so, Sl, s2 The 
hypnotic effects of trans buccal melatonin in 12 elderly patients with sleep 
maintenance insomnia failed to show any polysomnographic evidence for 
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improved sleep.S3 A study to evaluate melatonin treatment effects in 
normal sleepers and insomnia patients (age so years and older) revealed 
that significant improvements in sleep efficiency were noted at all dosage 
ranges of melatonin among subjects with insomnia but not among normal 
sleepers. 84 In another study of three different regimens of melatonin 
supplementation, only sleep latency was improved in those with age-
related sleep-maintenance insomnia. There were no significant 
differences in total sleep time, sleep efficiency, nighttime awakenings or 
daytime alertness compared to placebo. These results were noted even in 
low melatonin producers. ss In a study using a self-report questionnaire 
comparing melatonin treatment to placebo, no significant difference in 
sleep measurements was noted.sr 
Implications for Medical Practice 
Melatonin, for reasons discussed above, is an attractive alternative 
for elders suffering from insomnia. Benzodiazepines, which often are 
prescribed in this population, are associated with significant side effects, 
such as hospital admission and falls. 8s Although many questions remain 
regarding the use of melatonin for insomnia, namely who will likely 
benefit the most and at what dosage, melatonin's limited side effect profile 
and low cost should make it a reasonable option for a therapeutic trial, 
especially for those older patients on benzodiazepines. 
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Implications for Research 
Several areas of research need to be addressed. First, establishing 
an appropriate age cut-offfor age-related insomnia and second, the 
development of a precise definition of age-related insomnia. Other 
authors have included patients as young as so years of age in their 
investigation of the effects of melatonin on insomnia in older adults.ss 
Further research to determine the differences in etiology between age 
groups would be helpful in designing additional studies. 
Standardization of sleep assessment measures also would be helpful L 
' 
in future studies, as well as determining which of these correlates most 
consistently with subjective symptoms. Dosage standardization of 
melatonin is another area of concern. Many studies use varying amounts 
of melatonin and differing routes of administration, limiting generalizing 
results.s7 Additionally, any possible effects of melatonin on orthostasis 
should be further studied, especially among the elderly who may be more 
sensitive to orthostasis. 
Many studies have tried to use rigid exclusion criteria for 
enrollment. This methodology is problematic due to the significant 
amount of comorbidities and medications used in this population, some of 
which effect sleep quality (e.g., nocturia associated with benign prostatic 
hypertrophy, pain associated with osteoarthritis). For instance, in regards 
to concurrent medication usage, atenolol is a commonly prescribed 
antihypertensive in older adults and has been associated with attenuating 
melatonin secretion in human studies. Studies that are less restrictive 
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toward medication used and comorbidities may vastly increase sample 
sizes and also increase generalizability. 
Finally, outcome measurement of daytime dysfunction should be 
included in all studies. Poor objective sleep parameters should be 
correlated with factors such as daytime sleepiness and cognitive 
impairment, since much ofthe morbidity of insomnia is associated with 
these subjective measures. 
Conclusions 
A variety of different soporific agents are available to older persons 
suffering from insomnia. Although melatonin may be a safe alternative to 
standard hypnotic therapy, its use will be limited until more information is 
available regarding appropriate patient selection and dosing, especially 
when effective therapies exist (e.g., cognitive behavioral, standard 
hypnotics). This information will need to be obtained from much larger, 
well-designed, randomized controlled trials. 
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1 
<• : %~d) . . . i. >. · ••. .. . ·.·.. ... Comments 
Haimov, et a!. 1995 26 69-90 2mg Actigraphy None Fair 
I 
fast-release 1 week 2h Reportedt 
2mg Incomplete 
slow-release 1 week 2h exclusion 
lmg criteria 
slow-release 2 months 2h reported. 
Subjects 
less similar 
at baseline. 
Garfinkel, et a!. 1995 12 68-93 2mg 3 weeks 2h Actigraphy One case of Good 
slow-release pruritis in 
melatonin and Subjects 
placebo were usmg 
groups. benzodiazep 
ines. 
Garfinkel, et al. 1997 21 68-93 2mg 3 weeks 2h Actigraphy None Good 
slow-release Reportedt 
Subjects 
were usmg 
benzodiazep 
mes 
Baskett, et a!. 2003 20 65-84 5mg 4 weeks 30min* Actigraphy Drowsinesst Good 
immediate Sleep Diary 
release Questionnaire 
*not specifically noted, "on retiring to bed" 
tno significant difference compared to placebo 
tno mention of, or monitoring for, adverse events were reported in text 
Garfinkel, et I 75 (3; 
al. 1995 53-89) 
I <V.V I'·' I I <0.001 
nn AlA <"H+ 
<0.001 I 33 (7; 
10-102) 
Not reported 
<0.088 I 365 (20; 1360 (21; 
249-535) 212-508) 
<0.49 I 73 (13; 
10-179) 
NS 
for 2 
39.58 (7.6) 
41.2 (36.0, 
45.2) 
